Skip to main content
. 2016 May 6;11(5):e0154851. doi: 10.1371/journal.pone.0154851

Fig 3. Effects of MrgC agonist and anti-MrgC on expression levels of MrgC, Gi, and NR2B in spinal cord of BCP mice.

Fig 3

(A) The expression levels of MrgC, Gi, and NR2B in the spinal cord were detected with Western blot analysis, in sham mice, model control (Veh) mice, and model mice administered with BAM8-22 or anti-MrgC, at days 1, 3, and 7 after drug administration. (B-D) Statistical analyses of MrgC (B), Gi (C), and NR2B (D) expression levels after drug administration as indicated by Western blot analysis (n = 6). (E) Expression of MrgC (red) and NR2B (green) in the spinal cord were detected with immunohistochemistry in the sham mice, model control (vehicle) mice, and model mice treated with BAM8-22 or anti-MrgC (×200). (F-G) Statistical analyses of MrgC (F) and NR2B (G) expression levels after drug administration as indicated by immunohistochemistry (n = 6). Compared with the vehicle group, & P < 0.05; compared with the former time point, $ P < 0.05.